Radioactive 'Smart Bomb' targets Hard-to-Treat prostate cancer

NCT ID NCT05114746

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a radioactive drug called 177Lu-PSMA-617 in 94 Japanese men with advanced prostate cancer that had spread and stopped responding to hormone therapy. The drug seeks out and delivers radiation directly to cancer cells. Researchers measured how well it shrank tumors and how safe it was. The goal is to offer a new treatment option for this aggressive form of prostate cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 177Lu-PSMA-617 (a radioactive drug that targets prostate cancer cells)
What this could lead to: If successful, this could provide a new treatment option for men with advanced prostate cancer that has stopped responding to hormone therapy.
What could go wrong: This is a small, early-phase study (Phase 2) with no comparison group, so results may not confirm effectiveness. Radioactive drugs can cause side effects like dry mouth, fatigue, and low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Novartis Investigative Site

Kashiwa, Chiba, 277-8577, Japan
Novartis Investigative Site

Sapporo, Hokkaido, 060-8648, Japan
Novartis Investigative Site

Kobe, Hyōgo, 6500047, Japan
Novartis Investigative Site

Yokohama, Kanagawa, 236-0004, Japan
Novartis Investigative Site

Chiba, 260-8717, Japan
Novartis Investigative Site

Fukushima, 9601295, Japan
Novartis Investigative Site

Ishikawa, 9208641, Japan
Novartis Investigative Site

Kyoto, 6068507, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.